MedicosBiotech Wins CES 2025 Innovation Award in Digital Health
SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- MedicosBiotech proudly announces its recognition at CES 2025, the world's premier technology event, as a recipient of the prestigious CES Innovation Award in the Digital Health category. This award honors excellence in innovation, technology, and design, spotlighting MedicosBiotech's groundbreaking chronic wound care solution, Cure Silk. Cure Silk revolutionizes chronic wound...
Wearable Robotics Leading Company WIRobotics to Introduce Ultra-Lightweight Walking Assistance Wearable Robot WIM to the U.S. Market
Revolutionizing Personal Mobility and Healthcare for All Ages Proven Innovation Backed by CES Awards and Success in the Korean Market YONGIN, South Korea, Jan. 8, 2025 /PRNewswire/ -- WIRobotics, a pioneering leader in wearable robotics co-led by Yeon-baek Lee and Yong-jae Kim, is set to launch its breakthrough walking assistance wearable robot,...
Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease
Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. Supported by Insilico's commercially-available generative AI platform Chemistry42, the preclinical candidate (PCC) nomination of ISM5411 took only 12 months, during which approximately 115 molecules were...
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
SINGAPORE, Jan. 7, 2025 /PRNewswire/ -- SGX-listed iWOW Technology Limited ("iWOW" or the "Company"), a Singapore-based provider of IoT solutions, is thrilled to introduce two groundbreaking Age-Tech products at CES 2025 – the BOP Monitor and BOP Presence – which complement the existing BOP Button. These three products are part of a comprehensive suite of IoT solutions launched by...
Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing
SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the closing of RMB 550 million in Series C financing. Participating investors in this round include a renowned healthcare fund, Yangzhou Guojin Investment Group Co. LTD, and Kingray Capital....
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck...
Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's expertise and network, expanding clinical sites, and increasing patient enrollment. PHILADELPHIA, Jan. 7,...
Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment
TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on...
Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular Lens
HONG KONG, Jan. 7, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is proud to announce that our Phakic intraocular lens, "Loong Crystal PR", has received Class III Medical Devices Certificate from the National Medical...
U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented at the 2024 ASCO Annual Meeting SHANGHAI,...
